Survodutide (10mg)

Survodutide (BI 456906) is an investigational long-acting dual agonist of the GLP-1 receptor and glucagon receptor (GCGR) — a mechanistic combination that addresses two complementary aspects of energy balance simultaneously. While GLP-1 receptor agonism is well-established for appetite suppression, glycaemic control, and satiety enhancement, glucagon receptor co-activation provides the additional metabolic dimension of increased energy expenditure through hepatic gluconeogenesis suppression, thermogenesis, and hepatic fat mobilisation.

The dual GLP-1/GCGR mechanism is particularly compelling for non-alcoholic steatohepatitis (NASH) and metabolic liver disease research, where glucagon receptor activation drives preferential hepatic fat reduction and liver enzyme normalisation in addition to systemic weight reduction. Phase 2 clinical data demonstrates 12.5–14.9% body weight reduction at 46 weeks with survodutide, alongside significant liver fat content reduction.

Compared to GLP-1 monotherapy (semaglutide), survodutide's glucagon co-activation provides stronger liver-specific metabolic effects. Against tirzepatide (GLP-1 + GIP), survodutide replaces GIP with glucagon, producing different metabolic profiles particularly relevant in hepatic steatosis models. Against retatrutide (triple GLP-1/GIP/glucagon agonist), survodutide offers a potentially more balanced efficacy-tolerability profile.